Clinical Trials
11 trialsNCT00102648 2024-10-17
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT00102635 2018-11-15
4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00005030 2018-11-14
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00047502 2018-11-07
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00038584 2018-10-30
A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00083096 2015-02-10
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Unknown
NCT00003956 2013-04-04
Combination Chemotherapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00612651 2013-02-20
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Duke University
Phase 1 Completed
NCT00288444 2012-12-18
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Emory University
Phase 1 Terminated
NCT00068757 2012-09-12
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT00015899 2009-10-14
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
Pediatric Brain Tumor Consortium
Phase 1 Completed